Eupraxia Pharmaceuticals Files 6-K with Material Change Report
Ticker: EPRX · Form: 6-K · Filed: Sep 19, 2025 · CIK: 1581178
Sentiment: neutral
Topics: material-change, 6-k, foreign-private-issuer
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K on Feb 20, 2025, reporting a material change. Details to follow.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 19, 2025, reporting a Material Change Report dated February 20, 2025. The company, based in Victoria, British Columbia, Canada, is a pharmaceutical preparations company. Alex Rothwell, the Chief Financial Officer, signed the report.
Why It Matters
This filing indicates a significant event or change within Eupraxia Pharmaceuticals that was formally reported to the SEC, potentially impacting investors' understanding of the company's current status.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain material information that can lead to price volatility, and the nature of the 'material change' is not specified in this summary.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- Alex Rothwell (person) — Chief Financial Officer
- February 20, 2025 (date) — Date of Material Change Report
- September 19, 2025 (date) — Filing Date
FAQ
What specific material change was reported by Eupraxia Pharmaceuticals Inc. on February 20, 2025?
The provided 6-K filing does not specify the details of the material change, only that a report dated February 20, 2025, was included as Exhibit 99.1.
When was this Form 6-K filed with the SEC?
The Form 6-K was filed on September 19, 2025.
Who signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Alex Rothwell, the Chief Financial Officer, signed the report.
What is Eupraxia Pharmaceuticals Inc.'s primary business sector?
Eupraxia Pharmaceuticals Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Is Eupraxia Pharmaceuticals Inc. a US or foreign private issuer?
Eupraxia Pharmaceuticals Inc. is a foreign private issuer, as indicated by the Form 6-K filing and its Canadian address.
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2025-09-19 15:53:40
Filing Documents
- d82327d6k.htm (6-K) — 9KB
- d82327dex991.htm (EX-99.1) — 8KB
- 0001193125-25-209033.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc.. (Registrant) Date: September 19, 2025 /s/ Alex Rothwell Alex Rothwell Chief Financial Officer